Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer

NCT00338247 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00338247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00338247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Novartis
Phase
Expanded access
Overall status
Approved for marketing
Start date
July 31, 2006
Completion date
March 31, 2015
Enrollment
Not reported
Sites
453

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast